未登录

Y

Yun Chen

medicine

H指数:16

被引数:803

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Ubiquitin-centered post-translational modification crosstalk orchestrates tumor immunity and immunotherapy response

泛素为中心的翻译后修饰串扰调控肿瘤免疫和免疫治疗反应

Experimental Hematology & Oncology

IF13.5

2026-02-080

OAAI

Controllable Engineered Probiotic Hydrogel Coatings Prevent Drainage Tube-Associated Infections by Disrupting Pathogen Oxidative Stress Responses

Advanced Healthcare Materials

IF9.6

2026-01-190

PRE

Postoperative chemoradiotherapy for esophageal squamous cell Carcinoma: Results from ESO-Shanghai 17 and joint analyses for phase II clinical trials

食管鳞状细胞癌的术后化放疗：来自ESO-Shanghai 17和联合分析的II期临床试验结果

Clinical and Translational Radiation Oncology

IF2.7

2025-11-210

OAAI

Efficacy and safety analysis of China's first 10% IVIg (RonsenGlob) therapy in treating adult ITP

中国首款10% IVIg（RonsenGlob）疗法治疗成人ITP的疗效与安全性分析

ANNALS OF HEMATOLOGY

IF2.4

2025-05-100

OA

Intraoperative dual laparoscopy and neo-rectoscopy for precise excision of bowel endometriosis

IF12.8

2024-11-080

OAAI

Induction sintilimab and chemotherapy followed by concurrent chemoradiotherapy for locally advanced esophageal cancer: a proof-of-concept, single-arm, multicenter, phase 2 trial

ECLINICALMEDICINE

IF10

2024-03-018

OAAI

Hydrogen gas alleviates acute ethanol-induced hepatotoxicity in mice via modulating TLR4/9 innate immune signaling and pyroptosis

INTERNATIONAL IMMUNOPHARMACOLOGY

IF4.7

2024-01-014

OAAI

A phase II study of tislelizumab(T) as neoadjuvant treatment for cisplatin-ineligible high risk upper tract urothelial carcinoma (UTUC)

ANNALS OF ONCOLOGY

IF65.4

2023-11-010

PRE

The Impact of Obesity on Plastic Surgery Outcomes: A Systematic Review and Meta-Analysis

AESTHETIC SURGERY JOURNAL

IF3.9

2022-11-301

OA

Long-Term Results of a Phase 2 Study of Definitive Chemoradiation Therapy Using S-1 for Esophageal Squamous Cell Carcinoma Patients Who Were Elderly or With Serious Comorbidities

FRONTIERS IN ONCOLOGY

IF3.3

2022-04-052

OAAI

Cancer of Pharyngoesophageal Junction: A Different Subtype From Hypopharyngeal and Cervical Esophageal Cancer?

FRONTIERS IN ONCOLOGY

IF3.3

2021-11-021

OAAI

Involved-Field Irradiation in Definitive Chemoradiotherapy for Locoregional Esophageal Squamous Cell Carcinoma: Results From the ESO-Shanghai 1 Trial

INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS

IF6.5

2021-08-0121

PRE

The Prognosis and Feasibility of Extensive Clinical Target Volume in Postoperative Radiotherapy for Esophageal Squamous Cell Carcinoma: A Phase II Clinical Trial

FRONTIERS IN ONCOLOGY

IF3.3

2021-07-024

OAAI

Hydrogen protects lung from hypoxia/re-oxygenation injury by reducing hydroxyl radical production and inhibiting inflammatory responses

SCIENTIFIC REPORTS

IF3.9

2018-05-2224

OAAI

A randomized phase 3 trial comparing paclitaxel plus 5-fluorouracil versus cisplatin plus 5-fluorouracil in Chemoradiotherapy for locally advanced esophageal carcinoma-the ESO-shanghai 1 trial protocol

RADIATION ONCOLOGY

IF3.2

2018-02-2710

OAAI

A phase II study of concurrent chemoradiotherapy combined with a weekly paclitaxel and 5-fluorouracil regimen to treat patients with advanced oesophageal carcinoma

RADIATION ONCOLOGY

IF3.2

2017-03-078

OAAI

Evaluation of the value of ENI in radiotherapy for cervical and upper thoracic esophageal cancer: a retrospective analysis

RADIATION ONCOLOGY

IF3.2

2014-10-2546

OAAI

A NEIL1 Single Nucleotide Polymorphism (rs4462560) Predicts the Risk of Radiation-Induced Toxicities in Esophageal Cancer Patients Treated With Definitive Radiotherapy

IF5.1

2013-09-1028

PREAI